课题基金 / 基金详情

The Coming Revolution in HCV Therapy: Will HIV-HCV co-infected patients really benefit?

The Coming Revolution in HCV Therapy: Will HIV-HCV co-infected patients really benefit?
HCV 治疗即将到来的革命：HIV-HCV 共感染患者真的会受益吗？
批准号：
310032
负责人：
Klein Marina B
金额：
$0.0万
依托单位：
Research Institute of the McGill University Health Centre
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2014
资助国家：
加拿大
项目状态：
已结题
起止时间：
2014-03-01 至 2015-03-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=310032&lang=en
关键词：
Access To Treatment Cost-Effectivness Analysis Direct Antiviral Agents (Daas) End-Stage Liver Disease (Esld) Health Economics Health Outcomes Hepatitis C (Hcv) Hepatitis C Treatment Hiv Models Of Care

项目摘要

项目成果

Klein Marina B的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
HIV- Hepatitis C (HCV) co-infection is a growing concern across Canada. Evidence suggests that co-infected individuals advance faster to endstage liver disease (ESLD) compared to HCV mono-infected patients. Effective combination antiretroviral therapy ha
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
26th International Workshop on HIV and Hepatitis Observational Databases (IWHOD)
After the Cure: Measuring the full impacts of direct-acting antivirals for people living with HIV/hepatitis C virus coinfection in Canada
After the Cure: Measuring the full impacts of direct acting antivirals for people living with HIV/hepatitis C virus coinfection in Canada
5th International HIV/Viral Hepatitis Co-infection IAS Satellite Meeting